Skip to content
Annika Bansal – Lifestyle
Author:
Castle Biosciences, Inc.
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
March 9, 2026
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
March 6, 2026
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
March 5, 2026
←
Previous Page
1
2